Onco-Innovations Limited and Redwood AI, in collaboration with Canada’s Michael Smith Genome Sciences Centre and Centre de recherche du CHU de Québec-Université Laval, have been awarded a competitive Digital Health Innovation Fund grant administered by the Terry Fox Research Institute. The grant supports the development of the Onco SynoGraph AI-driven oncology platform, a project that aims to revolutionize the prediction of first-in-human clinical outcomes from preclinical studies and real-world clinico-genomic data.
The reimbursement-based grant covers up to 25% of an estimated $3.5 million project budget, underscoring the significance of this initiative in advancing cancer research. By leveraging federated learning and causal AI, the platform seeks to bridge the gap between preclinical research and clinical application, potentially accelerating the development of new cancer therapies and reducing the high failure rates associated with traditional drug development. This matters because oncology remains one of the most challenging areas in medicine, with countless promising treatments failing in early-stage trials. A tool that can more accurately predict human responses could save time, resources, and ultimately lives.
Redwood AI will contribute proprietary data integration and physicochemical modelling methods, while the academic partners will provide clinico-genomic and imaging data. Onco-Innovations will supply its causal AI methods and federated pipeline development. This collaborative approach highlights the growing trend of integrating AI into life sciences, where vast datasets and advanced algorithms can uncover insights that were previously inaccessible. For investors, this grant not only validates the technology but also signals potential for future commercialization.
The project's focus on federated learning is particularly noteworthy, as it allows for data privacy and security while enabling multiple institutions to collaborate on AI model training. This is crucial in healthcare, where patient data must be handled with the utmost care. By using causal AI, the platform aims to go beyond correlation and identify true cause-and-effect relationships, which is essential for reliable predictions. The involvement of the Terry Fox Research Institute adds further credibility, given its reputation for funding high-impact cancer research.
Onco-Innovations, a Canadian company dedicated to cancer research and treatment, holds an exclusive worldwide licence to patented technology for the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. This grant will support the company's broader mission to pursue prevention and treatment of cancer through pioneering research. Redwood AI, a technology company developing advanced artificial intelligence and cybersecurity solutions, applies AI across quantum cybersecurity, scientific research, and advanced chemistry applications. Their participation in this project aligns with their expertise in AI-driven solutions for life sciences.
The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF. The full press release can be viewed at https://ibn.fm/ySIj9. For more information about Onco-Innovations, visit Onco-Innovations Limited and Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ).
This announcement is disseminated by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. The platform aims to serve private and public companies seeking to reach a wide audience of investors, influencers, consumers, journalists, and the general public.
For full terms of use and disclaimers applicable to all content provided by BioMedWire, please visit https://www.BioMedWire.com/Disclaimer. The company’s website is www.BioMedWire.com.
